![Sheraz Mian Sheraz Mian](https://staticx.zacks.com/images/mugshots/sheraz_mian/sheraz_mian-4.png)
Top Research Reports for Intel, Novartis & Toyota
![](https://staticx.zacks.com/images/zt/ztNow_icon2.png)
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Monday, April 27, 2020
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Novartis (NVS) and Toyota Motor (TM). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Intel’s shares have underperformed the Zacks General Semiconductor industry over the past six months (+3.7% vs. +11.5%). The Zacks analyst believes that robust mix of high-performance second-generation Xeon Scalable processors and solid demand from Cloud service providers is expected to drive near-term growth.
The company is also making advancements in the IoT space, courtesy of product introductions and tie ups. Moreover, Intel is witnessing strong momentum for its first 10-nanometer (nm) mobile CPU.
Notably, the company has not provided 2020 guidance citing coronavirus crisis-induced business uncertainty. Further, declining PC total addressable market, higher expenses pertaining to 10-nm ramp up and constrained supply amid coronavirus outbreak in China remain concerns.
(You can read the full research report on Intel here >>>)
Shares of Novartis have gained +11% over the past year against the Zacks Large Cap Pharmaceuticals industry’s rise of +12.4%. The Zacks analyst believes that pipeline setbacks and generic competition for additional drugs are concerning.
Novartis has a strong oncology portfolio and a formidable generics business. The solid performance of key drugs like Cosentyx and Entresto, and contribution from gene therapy, Zolgensma, have boosted the performance in recent times and offset the impact of generic competition for legacy drugs. New launches like Piqray, Mayzent and Beovu should further boost sales.
The biosimilar portfolio also gains traction with new key approvals. The deep pipeline is encouraging as well. Novartis is also focusing on developing treatments for coronavirus and a positive outcome will boost the stock significantly. However, price erosion in the United States has adversely impacted the generics business.
(You can read the full research report on Novartis here >>>)
Toyota’s shares have lost -13.3% over the past three months against the Zacks Foreign Automotive industry’s fall of -18.4%. The Zacks analyst believes that expanding portfolio of product lines is driving Toyota’s prospects.
In order to capitalize on the accelerated global shift to electric cars, the auto giant of Japan is focusing on developing electric and autonomous vehicles. Toyota is working on hydrogen fuel stations in collaboration with various partners. The company aims to achieve half its global sales from electric vehicles by 2025. However, anticipating a slowdown in India, China, Indonesia and Thailand, the company narrowed its annual vehicle sales target for fiscal 2020.
Moreover, coronavirus woes and high research and development expenses on advanced technologies for the development of EVs and driverless cars are also likely to dent near-term margins. Its high debt levels also remain a concern. As such, investors are recommended to wait for a better entry point.
(You can read the full research report on Toyota here >>>)
Other noteworthy reports we are featuring today include Union Pacific (UNP), Southern (SO) and Biogen (BIIB).
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Get the latest research report on INTC - FREE
Get the latest research report on SO - FREE
Get the latest research report on NVS - FREE
Get the latest research report on BIIB - FREE
Get the latest research report on TM - FREE
Get the latest research report on UNP - FREE